Answers are grounded in this paper and cite their sources.
CAF-derived SPP1 enhances TKI resistance in HCC via bypass activation of oncogenic signals and EMT promotion. Its inhibition represents a promising therapeutic strategy against TKI resistance in HCC. Moreover, plasma SPP1 level before TKI treatment represents a potential biomarker for treatment response prediction.
No takes yet. Share an insight, caveat, or question.
Eun et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: